Orgel Wealth Management, LLC
13F filer · CIK 0001658535Reported Jul 13, 2026
Net buyer this quarter
13F portfolio value$5.27BU.S. long equity reported on 13F
Positions304 new · 1 closed
Net flow last quarter+$4.48MBuys minus sells
Top 10 positions weight6.1%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Jul 13, 202630 positions | |||||
| PBPMBSPuramed Bioscience Inc. | $240M | 4.56% | 2.44% | +1.1% | Q4 2024 |
| $66.3M | 1.26% | Not reported | -1.3% | Q4 2017 | |
| $4.94M | 0.09% | Not reported | +5.3% | Q4 2017 | |
| $2.99M | 0.06% | 0.00% | +32.3% | Q1 2016 | |
| $2.06M | 0.04% | 0.00% | +3.6% | Q3 2016 | |
| $1.96M | 0.04% | Not reported | 0.0% | Q1 2021 | |
| $1.44M | 0.03% | Not reported | +8.4% | Q3 2017 | |
| $1.23M | 0.02% | 0.00% | Not reported | Q4 2015 | |
| $849K | 0.02% | 0.00% | +6.5% | Q2 2018 | |
| $726K | 0.01% | 0.00% | Not reported | Q4 2021 | |
| $706K | 0.01% | 0.00% | -0.5% | Q4 2017 | |
| $603K | 0.01% | 0.00% | Not reported | Q1 2025 | |
| $541K | 0.01% | Not reported | +4.6% | Q1 2017 | |
| $512K | 0.01% | 0.00% | Not reported | Q2 2019 | |
| $486K | 0.01% | Not reported | +33.1% | Q2 2021 | |
| $484K | 0.01% | 0.00% | +4.9% | Q2 2019 | |
| $473K | 0.01% | 0.00% | +26.2% | Q1 2026 | |
| $420K | 0.01% | 0.00% | +7.3% | Q2 2019 | |
| $407K | 0.01% | 0.01% | Not reported | Q2 2017 | |
| $344K | 0.01% | Not reported | Not reported | Q4 2018 | |
| $340K | 0.01% | 0.00% | Not reported | Q4 2021 | |
| $336K | 0.01% | 0.00% | Not reported | Q4 2015 | |
| $317K | 0.01% | Not reported | +14.8% | Q4 2016 | |
| $316K | 0.01% | Not reported | -0.9% | Q1 2026 | |
| $270K | 0.01% | 0.00% | Not reported | Q4 2020 | |
| $261K | 0.00% | 0.00% | Not reported | Q3 2021 | |
| $237K | 0.00% | Not reported | Not reported | Q4 2015 | |
| $235K | 0.00% | 0.00% | Not reported | Q4 2019 | |
| $229K | 0.00% | 0.00% | +5.7% | Q4 2021 | |
| $203K | 0.00% | 0.00% | Not reported | Q4 2015 | |
| Q1 2026Reported Apr 7, 202627 positions | |||||
| PBPMBSPuramed Bioscience Inc. | $239M | 5.15% | 2.41% | +1.9% | Q4 2024 |
| $56.4M | 1.21% | Not reported | +1.8% | Q4 2017 | |
| $4.08M | 0.09% | Not reported | +0.2% | Q4 2017 | |
| $1.98M | 0.04% | 0.00% | -1.0% | Q1 2016 | |
| $1.97M | 0.04% | 0.00% | +2.6% | Q3 2016 | |
| $1.5M | 0.03% | Not reported | -3.1% | Q1 2021 | |
| $1.44M | 0.03% | 0.00% | Not reported | Q4 2015 | |
| $1.17M | 0.03% | Not reported | +17.2% | Q3 2017 | |
| $709K | 0.02% | 0.00% | Not reported | Q1 2025 | |
| $696K | 0.02% | 0.00% | +17.0% | Q2 2018 | |
| $525K | 0.01% | Not reported | -2.1% | Q1 2017 | |
| $472K | 0.01% | 0.00% | +10.8% | Q4 2017 | |
| $465K | 0.01% | 0.00% | -1.7% | Q2 2019 | |
| $449K | 0.01% | 0.00% | +7.4% | Q2 2019 | |
| $398K | 0.01% | 0.01% | Not reported | Q2 2017 | |
| $352K | 0.01% | 0.00% | -6.0% | Q2 2019 | |
| $338K | 0.01% | 0.00% | Not reported | Q4 2021 | |
| $329K | 0.01% | Not reported | +44.0% | Q4 2018 | |
| $323K | 0.01% | 0.00% | Not reported | Q4 2015 | |
| $301K | 0.01% | 0.00% | New | Q1 2026 | |
| $286K | 0.01% | Not reported | +35.9% | Q2 2021 | |
| $260K | 0.01% | 0.00% | Not reported | Q4 2020 | |
| $259K | 0.01% | Not reported | New | Q1 2026 | |
| $244K | 0.01% | Not reported | Not reported | Q4 2016 | |
| $233K | 0.01% | 0.00% | Not reported | Q4 2015 | |
| $213K | 0.00% | 0.00% | -4.5% | Q2 2025 | |
| $202K | 0.00% | 0.00% | -18.1% | Q4 2021 | |
| Q4 2025Reported Jan 7, 202626 positions | |||||
| PBPMBSPuramed Bioscience Inc. | $235M | 5.19% | 2.37% | +5.4% | Q4 2024 |
| $60.1M | 1.33% | Not reported | -1.9% | Q4 2017 | |
| $4.27M | 0.09% | Not reported | -0.6% | Q4 2017 | |
| $2.51M | 0.06% | 0.00% | +6.0% | Q3 2016 | |
| $2.15M | 0.05% | 0.00% | +9.1% | Q1 2016 | |
| $1.43M | 0.03% | Not reported | -0.8% | Q1 2021 | |
| $1.32M | 0.03% | 0.00% | Not reported | Q4 2015 | |
| $1.32M | 0.03% | 0.00% | New | Q4 2025 | |
| $974K | 0.02% | Not reported | -1.3% | Q3 2017 | |
| $660K | 0.01% | 0.00% | Not reported | Q1 2025 | |
| $660K | 0.01% | 0.00% | +13.9% | Q2 2018 | |
| $619K | 0.01% | Not reported | +5.9% | Q1 2017 | |
| $543K | 0.01% | Not reported | New | Q4 2025 | |
| $543K | 0.01% | 0.00% | +1.8% | Q2 2019 | |
| $477K | 0.01% | 0.00% | +4.4% | Q2 2019 | |
| $446K | 0.01% | 0.01% | Not reported | Q2 2017 | |
| $410K | 0.01% | 0.00% | +14.2% | Q2 2019 | |
| $376K | 0.01% | 0.00% | Not reported | Q4 2021 | |
| $344K | 0.01% | 0.00% | +18.8% | Q4 2017 | |
| $274K | 0.01% | 0.00% | Not reported | Q4 2015 | |
| $257K | 0.01% | 0.00% | +37.3% | Q4 2021 | |
| $255K | 0.01% | 0.00% | +4.7% | Q2 2025 | |
| $246K | 0.01% | 0.00% | Not reported | Q4 2020 | |
| $240K | 0.01% | Not reported | Not reported | Q4 2018 | |
| $224K | 0.00% | Not reported | -4.5% | Q2 2021 | |
| $215K | 0.00% | 0.00% | Not reported | Q4 2015 | |
| Q3 2025Reported Oct 6, 202525 positions | |||||
| PBPMBSPuramed Bioscience Inc. | $223M | 5.08% | 2.25% | +2.1% | Q4 2024 |
| $64.5M | 1.47% | Not reported | -0.8% | Q4 2017 | |
| $4.2M | 0.10% | Not reported | -5.3% | Q4 2017 | |
| $2.54M | 0.06% | 0.00% | -0.1% | Q3 2016 | |
| $1.84M | 0.04% | 0.00% | Not reported | Q1 2016 | |
| $1.34M | 0.03% | Not reported | Not reported | Q1 2021 | |
| $1.19M | 0.03% | 0.00% | +2.4% | Q4 2015 | |
| $975K | 0.02% | Not reported | +0.1% | Q3 2017 | |
| $651K | 0.01% | Not reported | Not reported | Q1 2017 | |
| $592K | 0.01% | 0.00% | Not reported | Q1 2025 | |
| $579K | 0.01% | 0.00% | Not reported | Q2 2019 | |
| $551K | 0.01% | 0.00% | Not reported | Q2 2018 | |
| $546K | 0.01% | 0.01% | Not reported | Q2 2017 | |
| $456K | 0.01% | 0.00% | Not reported | Q2 2019 | |
| $411K | 0.01% | 0.00% | Not reported | Q4 2021 | |
| $352K | 0.01% | 0.00% | -1.0% | Q2 2019 | |
| $261K | 0.01% | 0.00% | -0.3% | Q4 2020 | |
| $245K | 0.01% | 0.00% | -26.8% | Q4 2015 | |
| $241K | 0.01% | 0.00% | Not reported | Q4 2017 | |
| $240K | 0.01% | Not reported | Not reported | Q4 2018 | |
| $229K | 0.01% | Not reported | +4.7% | Q2 2021 | |
| $222K | 0.01% | 0.00% | Not reported | Q2 2025 | |
| $221K | 0.01% | 0.00% | -0.7% | Q4 2021 | |
| $220K | 0.01% | 0.00% | Not reported | Q3 2021 | |
| $211K | 0.00% | 0.00% | Not reported | Q4 2015 | |
Premium opens every quarter this fund has filed